NCT02599558

Brief Summary

This study is being done to see if the investigators can use only the cytosponge ( A 10 minute, in office procedure that does not require sedation) to replace the 6-10 endoscopies routinely perform during dietary restriction and food reintroduction in EoE?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

November 2, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 6, 2015

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 8, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 8, 2022

Completed
12 months until next milestone

Results Posted

Study results publicly available

December 30, 2022

Completed
Last Updated

December 30, 2022

Status Verified

December 1, 2022

Enrollment Period

6.2 years

First QC Date

November 2, 2015

Results QC Date

November 7, 2022

Last Update Submit

December 6, 2022

Conditions

Keywords

EOE

Outcome Measures

Primary Outcomes (1)

  • Histological Remission by Sponge Cytology

    Number of subject's sponge cytology to accurately detect histological remission when compared with standard of care EGD (defined as a peak eosinophil count of \<15 eos/hpf on endoscopic biopsy)

    approximately 4 weeks post food reintroduction

Secondary Outcomes (1)

  • Eosinophilic Esophagitis Activity Index Patient Reported Outcomes (EEsAI PRO) Score

    approximately 4 weeks post food reintroduction

Study Arms (1)

Cytosponge-directed food reintroduction

EXPERIMENTAL

Subjects will follow the six-food elimination diet per clinical protocol. The cytosponge will be used to monitor the diet at certain timepoints during food reintroduction

Device: Cytosponge

Interventions

A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.

Also known as: sponge
Cytosponge-directed food reintroduction

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with Eosinophilic Esophagitis \> than 15 Eos phf and failed to respond to the PPI therapy
  • Going through the six food elimination diet or have just completed elimination the six foods: fish, nuts, eggs, soy, wheat, and milk

You may not qualify if:

  • Clinical evidence of infectious process potentially contributing to dysphagia ( candidiasis, CMV, herpes)
  • Other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)
  • Esophageal minimal diameter \< 13 mm on structured barium esophagram

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Publications (1)

  • Alexander JA, Ravi K, Symrk TC, Wu TT, Lavey CJ, Geno D, Johnson AJ, Lennon RJ, Collins MH, Dellon ES, Katzka DA. Use of the Esophageal Sponge in Directing Food Reintroduction in Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2023 Feb;21(2):299-306.e3. doi: 10.1016/j.cgh.2022.05.029. Epub 2022 Jun 10.

Related Links

MeSH Terms

Conditions

Eosinophilic Esophagitis

Condition Hierarchy (Ancestors)

EsophagitisEsophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesGastroenteritisEosinophiliaLeukocyte DisordersHematologic DiseasesHemic and Lymphatic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Results Point of Contact

Title
Jeffrey A. Alexander, M.D.
Organization
Mayo Clinic

Study Officials

  • Jeffrey Alexander, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prinicipal Investigator

Study Record Dates

First Submitted

November 2, 2015

First Posted

November 6, 2015

Study Start

November 1, 2015

Primary Completion

January 8, 2022

Study Completion

January 8, 2022

Last Updated

December 30, 2022

Results First Posted

December 30, 2022

Record last verified: 2022-12

Locations